vs
Side-by-side financial comparison of IMAX CORP (IMAX) and Xeris Biopharma Holdings, Inc. (XERS). Click either name above to swap in a different company.
IMAX CORP is the larger business by last-quarter revenue ($125.2M vs $85.8M, roughly 1.5× Xeris Biopharma Holdings, Inc.). Xeris Biopharma Holdings, Inc. runs the higher net margin — 12.9% vs 0.5%, a 12.4% gap on every dollar of revenue. On growth, Xeris Biopharma Holdings, Inc. posted the faster year-over-year revenue change (42.8% vs 35.1%). Over the past eight quarters, Xeris Biopharma Holdings, Inc.'s revenue compounded faster (45.3% CAGR vs 25.8%).
IMAX Corporation is a Canadian production theatre company which designs and manufactures IMAX cameras and projection systems as well as performing film development, production, post-production and distribution to IMAX-affiliated theatres worldwide. Founded in Montreal in 1967, it has headquarters in the Toronto area, and operations in New York City and Los Angeles.
Xeris Biopharma Holdings, Inc. is a specialty biopharmaceutical company that develops and commercializes targeted therapies for rare endocrine, metabolic, and dermatological conditions. It operates across global markets, focusing on delivering accessible, easy-to-administer treatment options for underserved patient segments.
IMAX vs XERS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $125.2M | $85.8M |
| Net Profit | $637.0K | $11.1M |
| Gross Margin | 57.6% | — |
| Operating Margin | 19.3% | 19.5% |
| Net Margin | 0.5% | 12.9% |
| Revenue YoY | 35.1% | 42.8% |
| Net Profit YoY | -88.0% | 316.7% |
| EPS (diluted) | $0.02 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $125.2M | $85.8M | ||
| Q3 25 | $106.7M | $74.4M | ||
| Q2 25 | $91.7M | $71.5M | ||
| Q1 25 | $86.7M | $60.1M | ||
| Q4 24 | $92.7M | $60.1M | ||
| Q3 24 | $91.5M | $54.3M | ||
| Q2 24 | $89.0M | $48.1M | ||
| Q1 24 | $79.1M | $40.6M |
| Q4 25 | $637.0K | $11.1M | ||
| Q3 25 | $20.7M | $621.0K | ||
| Q2 25 | $11.3M | $-1.9M | ||
| Q1 25 | $2.3M | $-9.2M | ||
| Q4 24 | $5.3M | $-5.1M | ||
| Q3 24 | $13.9M | $-15.7M | ||
| Q2 24 | $3.6M | $-15.0M | ||
| Q1 24 | $3.3M | $-19.0M |
| Q4 25 | 57.6% | — | ||
| Q3 25 | 63.1% | — | ||
| Q2 25 | 58.5% | — | ||
| Q1 25 | 61.4% | — | ||
| Q4 24 | 52.2% | — | ||
| Q3 24 | 55.8% | — | ||
| Q2 24 | 49.4% | — | ||
| Q1 24 | 59.3% | — |
| Q4 25 | 19.3% | 19.5% | ||
| Q3 25 | 27.2% | 9.0% | ||
| Q2 25 | 15.6% | 6.3% | ||
| Q1 25 | 19.3% | -5.1% | ||
| Q4 24 | 10.3% | 2.8% | ||
| Q3 24 | 21.2% | -23.8% | ||
| Q2 24 | 3.2% | -17.0% | ||
| Q1 24 | 15.3% | -35.1% |
| Q4 25 | 0.5% | 12.9% | ||
| Q3 25 | 19.4% | 0.8% | ||
| Q2 25 | 12.3% | -2.7% | ||
| Q1 25 | 2.7% | -15.3% | ||
| Q4 24 | 5.7% | -8.5% | ||
| Q3 24 | 15.2% | -29.0% | ||
| Q2 24 | 4.0% | -31.2% | ||
| Q1 24 | 4.1% | -46.7% |
| Q4 25 | $0.02 | $0.07 | ||
| Q3 25 | $0.37 | $0.00 | ||
| Q2 25 | $0.20 | $-0.01 | ||
| Q1 25 | $0.04 | $-0.06 | ||
| Q4 24 | $0.09 | $-0.02 | ||
| Q3 24 | $0.26 | $-0.11 | ||
| Q2 24 | $0.07 | $-0.10 | ||
| Q1 24 | $0.06 | $-0.14 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $151.2M | $111.0M |
| Total DebtLower is stronger | — | $220.3M |
| Stockholders' EquityBook value | $337.9M | $13.7M |
| Total Assets | $894.0M | $383.5M |
| Debt / EquityLower = less leverage | — | 16.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $151.2M | $111.0M | ||
| Q3 25 | $143.1M | $91.6M | ||
| Q2 25 | $109.3M | $59.3M | ||
| Q1 25 | $97.1M | $58.4M | ||
| Q4 24 | $100.6M | $71.6M | ||
| Q3 24 | $104.5M | $69.4M | ||
| Q2 24 | $91.6M | $77.6M | ||
| Q1 24 | $81.0M | $87.4M |
| Q4 25 | — | $220.3M | ||
| Q3 25 | — | $219.5M | ||
| Q2 25 | — | $218.6M | ||
| Q1 25 | — | $229.8M | ||
| Q4 24 | — | $232.1M | ||
| Q3 24 | — | $216.2M | ||
| Q2 24 | — | $230.5M | ||
| Q1 24 | — | $229.7M |
| Q4 25 | $337.9M | $13.7M | ||
| Q3 25 | $349.5M | $-861.0K | ||
| Q2 25 | $320.4M | $-19.3M | ||
| Q1 25 | $299.5M | $-35.1M | ||
| Q4 24 | $299.5M | $-29.6M | ||
| Q3 24 | $289.4M | $-28.3M | ||
| Q2 24 | $267.2M | $-19.3M | ||
| Q1 24 | $258.8M | $-9.2M |
| Q4 25 | $894.0M | $383.5M | ||
| Q3 25 | $889.6M | $370.2M | ||
| Q2 25 | $868.6M | $334.7M | ||
| Q1 25 | $848.3M | $315.5M | ||
| Q4 24 | $830.4M | $323.1M | ||
| Q3 24 | $847.6M | $321.1M | ||
| Q2 24 | $827.4M | $331.7M | ||
| Q1 24 | $824.1M | $336.6M |
| Q4 25 | — | 16.10× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $29.4M | $20.0M |
| Free Cash FlowOCF − Capex | $28.0M | — |
| FCF MarginFCF / Revenue | 22.3% | — |
| Capex IntensityCapex / Revenue | 1.1% | — |
| Cash ConversionOCF / Net Profit | 46.11× | 1.81× |
| TTM Free Cash FlowTrailing 4 quarters | $118.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $29.4M | $20.0M | ||
| Q3 25 | $67.5M | $18.4M | ||
| Q2 25 | $23.2M | $182.0K | ||
| Q1 25 | $7.0M | $-10.0M | ||
| Q4 24 | $11.5M | $2.0M | ||
| Q3 24 | $35.3M | $-8.3M | ||
| Q2 24 | $35.0M | $-10.3M | ||
| Q1 24 | $-11.0M | $-20.3M |
| Q4 25 | $28.0M | — | ||
| Q3 25 | $64.8M | — | ||
| Q2 25 | $20.9M | — | ||
| Q1 25 | $5.3M | — | ||
| Q4 24 | $6.9M | — | ||
| Q3 24 | $34.2M | — | ||
| Q2 24 | $33.5M | — | ||
| Q1 24 | $-12.1M | — |
| Q4 25 | 22.3% | — | ||
| Q3 25 | 60.7% | — | ||
| Q2 25 | 22.8% | — | ||
| Q1 25 | 6.1% | — | ||
| Q4 24 | 7.4% | — | ||
| Q3 24 | 37.3% | — | ||
| Q2 24 | 37.6% | — | ||
| Q1 24 | -15.3% | — |
| Q4 25 | 1.1% | — | ||
| Q3 25 | 2.6% | — | ||
| Q2 25 | 2.6% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 5.0% | — | ||
| Q3 24 | 1.2% | — | ||
| Q2 24 | 1.8% | — | ||
| Q1 24 | 1.4% | — |
| Q4 25 | 46.11× | 1.81× | ||
| Q3 25 | 3.27× | 29.68× | ||
| Q2 25 | 2.06× | — | ||
| Q1 25 | 2.99× | — | ||
| Q4 24 | 2.16× | — | ||
| Q3 24 | 2.54× | — | ||
| Q2 24 | 9.78× | — | ||
| Q1 24 | -3.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IMAX
| Technology Sales | $46.6M | 37% |
| Image Enhancement And Maintenance Services | $38.1M | 30% |
| Joint Revenue Sharing Arrangement | $20.4M | 16% |
| Maintenance | $16.3M | 13% |
| Finance Income | $2.8M | 2% |
| Other Content Solutions | $1.6M | 1% |
XERS
| Products | $83.4M | 97% |
| Other | $2.4M | 3% |
